331 related articles for article (PubMed ID: 20801783)
1. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.
Mushtaq S; Warner M; Livermore DM
J Antimicrob Chemother; 2010 Nov; 65(11):2376-81. PubMed ID: 20801783
[TBL] [Abstract][Full Text] [Related]
2. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
Mushtaq S; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
[TBL] [Abstract][Full Text] [Related]
3. Activity of a novel combination against multidrug-resistant nonfermenters: ceftazidime plus NXL104.
Curcio D
Expert Rev Anti Infect Ther; 2011 Feb; 9(2):173-6. PubMed ID: 21342064
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
5. Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.
Mushtaq S; Warner M; Williams G; Critchley I; Livermore DM
J Antimicrob Chemother; 2010 Jul; 65(7):1428-32. PubMed ID: 20478991
[TBL] [Abstract][Full Text] [Related]
6. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.
Livermore DM; Mushtaq S; Ge Y; Warner M
Int J Antimicrob Agents; 2009 Nov; 34(5):402-6. PubMed ID: 19428220
[TBL] [Abstract][Full Text] [Related]
7. Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters.
Mushtaq S; Warner M; Livermore D
J Antimicrob Chemother; 2010 Feb; 65(2):266-70. PubMed ID: 19996139
[TBL] [Abstract][Full Text] [Related]
8. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.
Livermore DM; Mushtaq S; Warner M; Miossec C; Woodford N
J Antimicrob Chemother; 2008 Nov; 62(5):1053-6. PubMed ID: 18689875
[TBL] [Abstract][Full Text] [Related]
9. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa.
Livermore DM; Warner M; Mushtaq S
J Antimicrob Chemother; 2013 Oct; 68(10):2286-90. PubMed ID: 23696619
[TBL] [Abstract][Full Text] [Related]
10. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
[TBL] [Abstract][Full Text] [Related]
11. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
[TBL] [Abstract][Full Text] [Related]
12. Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters.
Mushtaq S; Woodford N; Hope R; Adkin R; Livermore DM
J Antimicrob Chemother; 2013 Jul; 68(7):1601-8. PubMed ID: 23449829
[TBL] [Abstract][Full Text] [Related]
13. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
[TBL] [Abstract][Full Text] [Related]
14.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
[TBL] [Abstract][Full Text] [Related]
15.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
[TBL] [Abstract][Full Text] [Related]
17. Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae.
Livermore DM; Mushtaq S; Doumith M; Jamrozy D; Nichols WW; Woodford N
J Antimicrob Chemother; 2018 Dec; 73(12):3336-3345. PubMed ID: 30247546
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
[TBL] [Abstract][Full Text] [Related]
19. Distribution of Ambler class A, B and D β-lactamases among Pseudomonas aeruginosa isolates.
Tawfik AF; Shibl AM; Aljohi MA; Altammami MA; Al-Agamy MH
Burns; 2012 Sep; 38(6):855-60. PubMed ID: 22348803
[TBL] [Abstract][Full Text] [Related]
20. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae.
Livermore DM; Mushtaq S; Warner M; Zhang J; Maharjan S; Doumith M; Woodford N
Antimicrob Agents Chemother; 2011 Jan; 55(1):390-4. PubMed ID: 21041502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
